Law360, New York (August 29, 2012, 3:23 PM EDT) -- Pliva Inc. and two other generic-drug makers have won the dismissal of a suit in Louisiana federal court that claimed a woman's movement disorder was caused by generic Reglan, ruling design defect and other allegations are preempted by the U.S. Supreme Court decision in Pliva Inc. v. Mensing.
Plaintiff Mildred Jacobsen claimed metoclopramide manufactured by Pliva, Actavis Inc., an Actavis subsidiary, and Northstar Rx LLC caused her tardive dyskinesia. Metaclopramide is the generic form of the diabetes medication Reglan.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.